Table 2.
Multiple myeloma characteristics in the two study groups before pretransplant therapy.
| Variables | VTD (n = 62) | VCD (n = 43) | p-Value * |
|---|---|---|---|
| Salmon-Durie staging | 0.124 | ||
| 1 | 5 (8.1%) | 3 (7.0%) | |
| 2 | 12 (19.4%) | 16 (37.2%) | |
| 3 | 45 (72.6%) | 24 (55.8%) | |
| Translocation t(4;14) | 9 (14.5%) | 7 (16.3%) | 0.804 |
| Chromosome 17p deletion | 5 (8.1%) | 5 (11.6%) | 0.540 |
| High GEP 70 risk score at diagnosis | 18 (29.0%) | 14 (32.6%) | 0.699 |
| High cytogenic risk | 17 (27.4%) | 12 (27.9%) | 0.956 |
| Karnosfky performance status ≥ 90 | 34 (54.8%) | 26 (60.5%) | 0.566 |
| Myeloma type | 0.887 | ||
| IgA | 13 (20.3%) | 10 (22.7%) | |
| IgG | 36 (56.3%) | 21 (47.7%) | |
| IgD | 4 (6.3%) | 4 (9.1%) | |
| Light Chain | 7 (10.9%) | 4 (9.1%) | |
| Nonsecretory | 2 (3.1%) | 2 (4.5%) | |
| Others | 2 (3.1%) | 3 (6.8%) | |
| Positive urine immunofixation | 34 (54.8%) | 25 (58.1%) | 0.737 |
* Chi-squared or Fisher’s exact test; GEP70—gene expression profiling.